文献速递类风湿关节炎

TNFi联合甲氨蝶呤与三联疗法治疗类风湿关节炎的系统综述与网络荟萃分析

Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.
PubMed 文献 · RMD Open · 2017-01-03

该系统综述与网络荟萃分析纳入33项甲氨蝶呤应答不佳和19项甲氨蝶呤初治的随机对照试验,比较TNFi联合甲氨蝶呤与三联疗法在类风湿关节炎中的疗效与安全性。在应答不佳患者中,三联疗法达到ACR70的比值比低于TNFi联合甲氨蝶呤(OR 0.35,95%CrI 0.19至0.64),但感染比值比更低(OR 0.08,95%CrI 0.00至0.57);初治患者中两方案无差异。

要点

  • 甲氨蝶呤应答不佳者中,三联疗法6个月ACR70应答几率低于TNFi联合甲氨蝶呤。
  • 甲氨蝶呤应答不佳者中,三联疗法感染几率低于TNFi联合甲氨蝶呤。
  • 甲氨蝶呤初治患者中,两方案在疗效与安全性上未观察到差异。

核心结论

  • 在甲氨蝶呤应答不佳的类风湿关节炎患者中,三联疗法6个月达到ACR70的几率比TNFi联合甲氨蝶呤低65%。
  • TNFi联合甲氨蝶呤的感染几率高于三联疗法,但其他次要终点无明确差异。
  • 在甲氨蝶呤初治患者中,两方案未观察到差异。

研究设计与样本

  • 系统综述与网络荟萃分析,纳入TNFi联合甲氨蝶呤或三联疗法为治疗臂的随机对照试验。
  • 分析33项甲氨蝶呤应答不佳研究和19项甲氨蝶呤初治研究。
  • 主要终点为6个月ACR70应答率,采用固定效应和随机效应贝叶斯模型进行直接与间接比较。

主要发现

  • 甲氨蝶呤应答不佳患者中,三联疗法对比TNFi联合甲氨蝶呤的ACR70 OR为0.35(95%CrI 0.19至0.64)。
  • 甲氨蝶呤应答不佳患者中,三联疗法对比TNFi联合甲氨蝶呤的感染OR为0.08(95%CrI 0.00至0.57)。
  • 多数次要终点OR方向倾向于TNFi联合甲氨蝶呤,但未观察到明确的达成几率增加。
  • 甲氨蝶呤初治患者中两方案未观察到差异。

关键数值与推荐

  • 主要终点为6个月ACR70应答标准。
  • 甲氨蝶呤应答不佳者中,三联疗法ACR70 OR 0.35(95%CrI 0.19至0.64),感染OR 0.08(95%CrI 0.00至0.57)。

临床怎么用

  • 对于甲氨蝶呤应答不佳的类风湿关节炎患者,选择TNFi联合甲氨蝶呤可能提高深度应答几率,但需权衡感染风险。
  • 三联疗法在甲氨蝶呤应答不佳者中感染风险较低,可作为考虑方案。
  • 甲氨蝶呤初治患者中两方案无差异,选择可综合其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinical trials have not consistently demonstrated differences between tumour necrosis factor inhibitor (TNFi) plus methotrexate and triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in rheumatoid arthritis (RA). The study objective was to estimate the efficacy, radiographic benefits, safety and patient-reported outcomes of TNFi-methotrexate versus triple therapy in patients with RA. METHODS: A systematic review and network meta-analysis (NMA) of randomised controlled trials of TNFi-methotrexate or triple therapy as one of the treatment arms in patients with an inadequate response to or who were naive to methotrexate was conducted. American College of Rheumatology 70% response criteria (ACR70) at 6 months was the prespecified primary endpoint to evaluate depth of response. Data from direct and indirect comparisons between TNFi-methotrexate and triple therapy were pooled and quantitatively analysed using fixed-effects and random-effects Bayesian models. RESULTS: We analysed 33 studies in patients with inadequate response to methotrexate and 19 in patients naive to methotrexate. In inadequate responders, triple therapy was associated with lower odds of achieving ACR70 at 6 months compared with TNFi-methotrexate (OR 0.35, 95% credible interval (CrI) 0.19 to 0.64). Most secondary endpoints tended to favour TNFi-methotrexate in terms of OR direction; however, no clear increased likelihood of achieving these endpoints was observed for either therapy. The odds of infection were lower with triple therapy than with TNFi-methotrexate (OR 0.08, 95% CrI 0.00 to 0.57). There were no differences observed between the two regimens in patients naive to methotrexate. CONCLUSIONS: In this NMA, triple therapy was associated with 65% lower odds of achieving ACR70 at 6 months compared with TNFi-methotrexate in patients with inadequate response to methotrexate. Although secondary endpoints numerically favoured TNFi-methotrexate, no clear differences were observed. The odds of infection were greater with TNFi-methotrexate. No differences were observed for patients naive to methotrexate. These results may help inform care of patients who fail methotrexate first-line therapy.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Fleischmann R, Tongbram V, van Vollenhoven R, et al. Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open. 2017. PMID: 28123782. doi:10.1136/rmdopen-2016-000371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。